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Abstract
Polycomb group (PcG) genes contribute to the main-
tenance of cell identity, cell cycle regulation, and
oncogenesis. We describe the expression of five PcG
genes (BMI-1,RING1,HPC1,HPC2, andEZH2) in normal
breast tissues, invasive breast carcinomas, and their
precursors. Members of the HPC–HPH/PRC1 PcG
complex, including BMI-1, RING1, HPC1, and HPC2,
were detected in normal resting and cycling breast
cells. The EED–EZH/PRC2 PcG complex protein EZH2
was only found in rare cycling cells, whereas normal
resting breast cells were negative for EZH2. PcG gene
expression patterns in ductal hyperplasia (DH), well-
differentiated ductal carcinoma in situ (DCIS), and well-
differentiated invasive carcinomas closely resembled
the pattern in healthy cells. However, poorly differ-
entiated DCIS and invasive carcinomas frequently
expressed EZH2 in combination with HPC–HPH/PRC1
proteins. Most BMI-1/EZH2 double-positive cells in
poorly differentiated DCIS were resting. Poorly differ-
entiated invasive carcinoma displayed an enhanced
rate of cell division within BMI-1/EZH2 double-positive
cells. We propose that the enhanced expression of
EZH2 in BMI-1+ cells contributes to the loss of cell
identity in poorly differentiated breast carcinomas, and
that increased EZH2 expression precedes high fre-
quencies of proliferation. These observations suggest
that deregulated expression of EZH2 is associated with
loss of differentiation and development of poorly
differentiated breast cancer in humans.
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Introduction
Polycomb group (PcG) proteins play a key role in the
maintenance of cell identity [1–3] and contribute to the
regulation of various processes, including lymphocyte de-
velopment [4–6] and the cell cycle [7,8]. PcG proteins
function as large multimeric complexes [9], containing var-
ious enzymes involved in the modification of histone tails
[10–14]. This suggests that stable gene silencing by PcG
complexes is related to alteration of chromatin composition.
Two of these complexes have been identified and were shown
to be evolutionarily conserved. The HPC–HPH ‘‘maintenance
complex’’ is the mammalian counterpart of polycomb repres-
sive complex-1 (PRC1) in Drosophila [15,16] and consists of
the BMI-1, RING1, HPC, and HPH PcG proteins [17–22]. The
mammalian EED–EZH complex is similar to the Drosophila
Esc-E(Z)/PRC2 ‘‘initiation complex’’ [23,24] and contains the
EED, EZH, and YY1 PcG proteins [25–28]. PcG complexes
exhibit cell type–specific composition, which is most likely
related to their specificity for different target genes [9,29].
The role of PcG genes in the maintenance of cell identity is
underscored by the fact that several PcG genes can be
classified as oncogenes and tumor suppressor genes [30,31].
For instance, overexpression of HPC2, RING1, and BMI-1 in
experimental model systems resulted in cellular transformation
of cell lines, or produced lymphomas in mutant mice
[22,32–35]. Whether PcG genes are capable of producing
cancer in humans is unclear, but recent studies that addressed
this question concluded that neoplastic cells are associated
with altered expression of PcG genes. For instance, Reed-
Sternberg cells of Hodgkin’s lymphoma and neoplastic cells in
B-NHL display altered expression of BMI-1 [36,37]. Recent
studies of human solid tumors demonstrated that BMI-1 is
differentially expressed in non small cell lung cancer [38],
whereas disease progression in prostate cancer, which shows
many similarities to breast cancer, appears related to upregu-
lation of EZH2 [39,40].
In this paper, we describe the expression of the BMI-1,
RING1, HPC1, HPC2, and EZH2 PcG proteins in normal breast
tissues, invasive breast carcinomas, and their precursors by
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means of conventional tissue sections and tissue arrays. We
found that poorly differentiated ductal carcinoma in situ
(DCIS) and poorly differentiated invasive carcinoma dis-
played enhanced expression of EZH2 in cells using PcG
proteins of the HPC–HPH/PRC1 complex. This pattern was
associated with an increased frequency of cell proliferation in
EZH2-positive cells of invasive carcinomas, and suggests
that altered EZH2 expression is related to loss of differenti-
ation in breast carcinomas.
Materials and Methods
Human Tissue
Four normal breast tissues, 20 preinvasive breast lesions,
and 15 invasive breast lesions were collected from the
archives of the Department of Pathology of the VU University
Medical Center (Amsterdam, The Netherlands). Anonymous
use of leftover tumor material is part of the standard treat-
ment agreement with patients in our hospital [41]. The
normal breast tissues, obtained from breast reduction sur-
gery, had no indications for the presence of hyperplasia, (in
situ) carcinoma, fibroadenoma, or papilloma. Only adjacent
nonproliferative changes, such as apocrine metaplasia, duct
ectasia, or sclerosing adenosis, could be present. Preinva-
sive lesions were classified according to the criteria of Page
et al. [42,43] and included four usual ductal hyperplasias
(DHs), six atypical DHs, five well-differentiated, and five
poorly differentiated ductal carcinomas in situ (DCIS). All
preinvasive lesions were ‘‘pure,’’ meaning that there were no
more advanced stages present (no invasion in the case of
DCIS; no DCIS or invasion in the case of hyperplasia).
Invasive breast carcinomas were graded according to the
Elston and Ellis Grading System [44] and included four grade
I (well-differentiated), six grade II (intermediately differenti-
ated), and five grade III (poorly differentiated) lesions. A
tissue microarray containing 172 invasive breast cancer
cases with long-term follow-up was constructed as described
before [45].
PcG Protein Detection by Immunohistochemistry
Four-micrometer sections were cut from paraffin-embed-
ded tissues and mounted on Superfrost Plus slides (Omni-
labo, Breda, The Netherlands). Following deparaffinization,
endogenous peroxidase was inhibited by incubation of the
tissue sections for 30 minutes at room temperature in 0.3%
H2O2, diluted in methanol. Antigens were retrieved by boiling
for 10 minutes in citrate buffer (pH = 6), followed by succes-
sive rinses in phosphate-buffered saline (PBS) containing
0.5% Triton (1  5 minutes), and PBS only (3  5
minutes). Slides were then incubated for 10 minutes in 0.1
M glycine (diluted in PBS), and rinsed in PBS only (3  5
min). Expression of PcG expression was detected using
monoclonol and polyclonal antisera directed against PcG
proteins [20,22,25,32], as indicated in Table 1. Tissues of
known PcG reactivity were included in each experiment as
positive controls for antiserum reactivity, and negative con-
trols were obtained by omission of primary antibodies. Be-
fore application of the primary antiserum or antibody,
sections were incubated for 10 minutes in normal swine
serum (diluted 1:10 in PBS + 1% BSA) or normal rabbit
serum (diluted 1:50 in PBS + 1% BSA). Secondary antisera
were biotinylated goat antimouse or biotinylated swine anti-
rabbit. Immunostaining was performed with 3-amino-9-ethyl-
carbazole (AEC) using the streptavidin–biotin complex/
horseradish peroxidase (sABC-HRP) method and tyramine
intensification, or with diaminobenzidine (DAB)/peroxidase
and imidazole intensification. Sections were briefly counter-
stained with hematoxylin. Photographs were taken with a
Zeiss Axiophot microscope (Zeiss, Oberkochen, Germany)
and digitized using an Agfa duoscan scanner (Agfa, Mortsel,
Belgium). The tissue microarray was stained for EZH2 only.
Immunofluorescence Double and Triple Staining
Double immunofluorescence stainings with antisera
against BMI-1, EZH2, and MIB-1/Ki-67 were performed on
3-mm frozen sections. After fixation in 2% formaldehyde,
endogenous peroxidase was inhibited with 1% H2O2, diluted
in PBS. Sections were preincubated with 5% BSA, and
primary antibodies against BMI-1 and EZH2 were applied
in combination with antiserum against MIB-1/Ki-67. BMI-1
was detected by incubation with GaMIgG2b
HRP using the
streptavidin–biotin–avidin complex/HRP method and rho-
damine/tyramine intensification (excitation 550, emission
570; red fluorescence). EZH2 was detected by incubation
with GaR antiserum coupled to ALEXA (excitation 495,
emission 519; green fluorescence). MIB-1/Ki-67 was
detected by incubating the slides with GaMIgG1
BIO, followed
by incubation with StrepAPC [streptavidin coupled to allophy-
cocyanin (excitation 650, emission 660); infrared interpreted
as blue fluorescence by the computer]. Cross-reactivity of
the antisera was excluded by appropriate controls, and PcG
expression patterns were confirmed in at least three sepa-
rate experiments on tissues derived from different individu-
als. Sections were analyzed with a Leica DMR Confocal
LaserScan microscope (Leica, Rijswijk, The Netherlands).
Images were stored digitally at 1024 dpi and processed using
Corel Photo-Paint 8.
Results
PcG Expression in Normal Breast Tissue
We first determined the nuclear expression of BMI-1,
RING1, HPC1, HPC2, and EZH2 in normal breast ducts by
immunohistochemistry. Normal breast ducts primarily
expressed PcG proteins belonging to the HPC–HPH/PRC1
Table 1. Overview of the Different PcG Antibodies Used.
Target Antibody Source Dilution
BMI-1 6C9 Mouse monoclonal Undiluted
RING1 K320 Rabbit polyclonal 1:100
HPC1 K350 Rabbit polyclonal 1:100
HPC2 K326 Rabbit polyclonal 1:100
EZH2 K358 Rabbit polyclonal 1:100
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complex (Table 2, Figure 1). The majority of myoepithelial
cells (outer layer) strongly expressed BMI-1, RING1, and
HPC2, with HPC1 being detectable but at an apparently lower
intensity (Figure 1, A and E). Most columnar epithelial cells
(inner layer) weakly expressed BMI-1, RING1, and HPC1,
with a minority of these cells being strongly positive for HPC2.
Expression EED–EZH/PRC2 complex protein EZH2 was
virtually undetectable in normal ducts (Figure 1I). Only very
occasionally, a positive nucleus was seen in premenopausal
breast tissues, including a positive mitotic figure.
We then used immunofluorescence double and triple
staining for BMI-1 and EZH2 to confirm the expression of
the HPC–HPH/PRC1 and EED–EZH/PRC2 complexes in
normal breast tissues. The majority of epithelial cells
expressed the BMI-1 protein, confirming widespread expres-
sion of BMI-1 (Figure 2A, red fluorescence). EZH2 expres-
sion was rarely detected and always associated with cycling
cells. This is illustrated by colocalization of the signal for
EZH2 (Figure 2B, green fluorescence) and MIB-1/Ki-67
(Figure 2D, blue fluorescence) in Figure 2. Note that the
EZH2/MIB-1 double-positive cycling cell has retained ex-
pression of BMI-1 (Figure 2, C and E).
PcG Expression in Preinvasive Lesions
PcG expression was analyzed in lesions through which
invasive breast cancer is thought to develop [46,47], includ-
ing usual and atypical DH, and DCIS. Expression of genes
encoding the HPC–HPH PcG complex resembled that of
normal tissues or appeared slightly increased (Table 2,
Figure 1, B, C, F, and G). In DH, most cells expressed
HPC2 and were variably positive for BMI-1, RING1, and
HPC1. In DCIS, neoplastic cells strongly expressed BMI-1,
RING1, and HPC2, with HPC1 being detectable at variable
levels. There were no obvious differences in the detection of
PcG proteins belonging to the HPC–HPH/PRC1 complex
between well differentiated and poorly differentiated DCIS.
In contrast to normal tissues, expression of the EZH2
PcG protein was frequently detected in poorly differentiated
DCIS, but only sporadically in DH or well differentiated
DCIS (Table 2, Figure 2, J and K). Analysis of these
Table 2. PcG Expression in Normal Breast Tissues, Invasive Breast
Carcinomas, and Precursors.
Tissue BMI-1 RING1 HPC1 HPC2 EZH2
Healthy (n = 4) 3 4 2 3 1
DH, usual type
(n = 4)
4 4 1 4 1
Atypical DH
(n = 6)
4 4 1 4 1
DCIS, well differentiated
(n = 5)
4 4 2 4 1
DCIS, poorly differentiated
(n =5)
4 4 1 4 2
Invasive carcinoma,
well differentiated (n = 4)
4 3 1 4 1
Invasive carcinoma,
intermediately differentiated
(n = 6)
4 4 1 4 1
Invasive carcinoma, poorly
differentiated (n = 5)
4 4 1 4 3
Nuclear PcG gene expression was investigated using immunohistochemistry
and PcG-specific antibodies. Neoplastic cells were scored as follows: 1 = 0–
25% positive cells; 2 = 26–50% positive cells; 3 = 51–75% positive cells; 4 =
>75% positive cells.
Figure 1. Expression of PcG genes in normal breast glands, invasive carcinomas, and their precursor lesions. Shown is the nuclear expression pattern of the BMI-
1 (A–D), RING1 (E–H), and EZH2 (I –L) PcG genes in normal breast tissues (A, E, I), ductal hyperplasia (B, F, J), well-differentiated DCIS (C and G), poorly
differentiated DCIS (K), and invasive carcinoma (D, H, L).
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tissues by immunofluorescence double and triple staining
confirmed that EZH2 expression was widespread in neo-
plastic cells of poorly differentiated DCIS, and infrequent in
well-differentiated DCIS and DH. In Figure 3, A–D, a case
of poorly differentiated DCIS is shown, where combination
of the BMI-1 signal (red fluorescence) and the EZH2 signal
(green fluorescence) produces a yellow signal in the nu-
cleus of BMI-1/EZH2 coexpressing cells (Figure 3C).
Whereas expression of EZH2 in normal epithelial cells of
breast glands was associated with cell division (Figure 2, C
and E), BMI-1/EZH2 double-positive cells in DH and DCIS
were resting in most instances. As shown in Figure 3, A–
D, the majority of BMI-1/EZH2 double positive in poorly
differentiated DCIS cells did not express MIB-1/Ki-67.
PcG Expression in Invasive Carcinomas
Invasive breast carcinomas expressed HPC–HPH/PRC1
complex proteins in a pattern similar to that of preinvasive
lesions. BMI-1, RING1, and HPC2 were strongly expressed
in invasive neoplastic cells, with variable nuclear positivity for
HPC1 (Table 2). This pattern of expression was similar in
well-differentiated invasive carcinomas, and intermediately
or poorly differentiated carcinomas. As noted for DCIS
lesions, detection of the EED–EZH/PRC2 complex protein
EZH2 depended on differentiation grade. EZH2 was most
frequently detected in the majority of neoplastic cells of
poorly differentiated invasive carcinomas (Table 2), whereas
well-differentiated and intermediately differentiated lesions
were mostly negative for EZH2. This positive correlation
between EZH2 expression and histologic grade was con-
firmed on the tissue microarray (P < .004, chi-square test).
EZH2 expression was analyzed in 172 tumors, graded G1
(n = 24), G2 (n = 96), and G3 (n = 52). Of these tumors, 4.2%,
11.5%, and 53.8% stained for EZH2, respectively. EZH2 did,
however, not have prognostic values in Kaplan-Mayer sur-
vival analysis (log rank test).
We next confirmed the expression pattern of EZH2 in
relation with BMI-1 and MIB-1/Ki-67 in invasive carcinomas
by imunofluorescence double and triple staining. An exam-
ple of a poorly differentiated invasive carcinoma is shown in
Figure 3, E–H, and of a well-differentiated invasive carci-
noma in Figure 3, I–L. Neoplastic cells in well-differentiated
invasive carcinomas were all BMI-1+ and expressed MIB-1/
Ki-67 (Figure 3, I and J). Low-level EZH2 expression was
detected in a minority of these cells (Figure 3K, arrows).
Detection of BMI-1, EZH2, and MIB-1/Ki-67 in poorly
differentiated lesions (Figure 3, E–H) revealed a highly
diverse pattern in neoplastic cells. The vast majority of
these cells were MIB-1+ and expressed BMI-1 (Figure 3E).
EZH2 expression was more frequent than in well-differen-
tiated invasive carcinomas and was detected at varying
levels of intensity. This is illustrated by the ‘‘autumn leaf
expression pattern’’ of BMI-1 and EZH2 in Figure 3G.
Combination of the three immunofluorescent signals
showed that poorly differentiated invasive carcinomas
contained highly diverse populations of neoplastic cells with
extensive fluctuation in expression of BMI-1, EZH2, and
MIB-1 (Figure 3H).
Discussion
PcG genes form a ‘‘cellular memory system’’ that is
essential for the maintenance of cell identity by preserving
gene silencing patterns after cell division [1–3]. Various
Figure 2. Expression of BMI-1, EZH2, and MIB-1 in normal breast glands. BMI-1, EZH2, and MIB-1 were detected by red, green, and blue fluorescence,
respectively. The majority of cells in normal breast glands express BMI-1 (red signal) and are resting (as indicated by the relative absence of staining for MIB-1).
Rare cycling MIB-1POS cells (blue signal) are occasionally visible. These cells retain expression of BMI-1 and are faintly stained for EZH2 (see insets and details, a
BMI-1+/EZH2+/MIB-1+ cell is indicated by an arrow).
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processes, including regulation of the cell cycle and he-
matopoiesis, were recently shown to be controlled by PcG
genes [4–8]. The essential role of PcG genes in these
processes is underscored by the relationship between
inordinate PcG gene expression and malignant transfor-
mation. The best known example is induction of lympho-
mas in BMI-1 transgenic mice, where upregulation of
BMI-1 results in downregulation of the cell cycle regulators
p16INK4a/p19ARF [35,48]. Investigation of BMI-1 in human
malignancies showed altered expression patterns in Hodg-
kin’s lymphoma [36], B-cell non-Hodgkin’s lymphoma
[37,49], and lung carcinoma [38], suggesting that human
BMI-1 may also contribute to oncogenic transformation.
Yet, despite these observations, our knowledge of a role
for PcG genes in human tumors remains limited.
In the current paper, we describe the expression pattern
of individual PcG genes in healthy breast gland cells and
tumors derived from these cells. We showed that healthy
resting breast gland cells primarily express PcG genes
encoding the HPC–HPH/PRC1 PcG complex, including
BMI-1, RING1, HPC1, and HPC2. In contrast, rare dividing
cells were associated with expression of the EZH2 gene
belonging to the EED–EZH/PRC2 PcG complex. This ex-
pression pattern is reminiscent of the PcG expression profile
of healthy mature lymphoid cells, where expression of BMI-1
is associated with resting lymphocytes whereas EZH2 is
found in dividing cells [50,51]. Of note is, however, that BMI-
1 remains detectable in healthy cycling breast gland cells,
whereas BMI-1 expression is lost in cycling lymphocytes.
The most likely explanation for this disparity is that breast
gland cells and lymphocytes have different cellular identities.
They are, therefore, expected to possess distinct patterns of
PcG gene expression, which is in line with the observation
that the HPC1 PcG protein is detectable in breast gland
Figure 3. Immunofluorescence detection of BMI-1, EZH2, and MIB-1 in breast carcinomas. Expression of BMI-1, EZH2, and MIB-1 was determined in poorly
differentiated DCIS (A–D), poorly differentiated invasive carcinoma (E–H), and well-differentiated invasive carcinoma (I –L). Nuclear expression of BMI-1, EZH2,
and MIB-1 was detected by red, green, and blue fluorescence, respectively. Shown are double fluorescence images of BMI-1 + MIB-1 (A, E, I), EZH2 + MIB-1
(B, F, J), BMI-1 + EZH2 (C, G, K), and triple immunofluorescence for BMI-1, EZH2, and MIB-1 (D, H, L). In DCIS of poor differentiation, widespread expression of
BMI-1 (A) and EZH2 (B) resulted in frequent coexpression of BMI-1 and EZH2 in neoplastic cells (C). Only a limited number of these cells were MIB-1POS and
cycling (A, B, D). Neoplastic cells in badly differentiated invasive carcinoma also displayed widespread expression of BMI-1 (E) and EZH2 (F), leading to frequent
BMI-1/EZH2 coexpression (G). In contrast to badly differentiated DCIS, the majority of the BMI-1+/EZH2+ cells were MIB-1+ (blue signal in E, F, and H) and cycling.
The majority of neoplastic cells in well-differentiated invasive carcinoma were BMI-1+ (I and K) and growing (as indicated by the blue signal in J and L). In contrast
to poorly differentiated tumors, however, expression of EZH2 was infrequent, as indicated by the rare occurrence of neoplastic cells that faintly stained for EZH2
(indicated by the arrows in I –L).
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cells, whereas mature lymphocytes do not express HPC1
(van Galen and Raaphorst, in preparation).
Neoplastic cells in DH, DCIS, and invasive carcinoma
displayed frequent and strong staining for core proteins of
the HPC–HPH/PRC1 complex, including BMI-1, RING1,
HPC1, and HPC2. Because several of these proteins have
been associated with oncogenic properties, the question
arises as to whether they contribute to the development of
breast cancer. Earlier studies of the BMI-1 binding partner
Mel-18 demonstrated that its expression levels are de-
creased in human breast cancer cell lines, and that hap-
loinsufficiency for this gene predisposes mice to the
development of mammary tumors [52]. In addition, over-
expression of BMI-1 in human mammary epithelial cells
resulted in downregulation of the cell cycle regulators
p16INK4a/p19ARF, upregulation of telomerase, and immor-
talization [34,35,48]. These results suggest that PcG pro-
teins of the HPC –HPH/PRC1 complex are likely
contributing factors in the development of breast tumors.
We observed that normal breast gland cells stain for BMI-1
and its binding partners with variable intensity, whereas
staining of neoplastic cells was frequent and strong. This
might suggest that HPC–HPH/PRC1 genes are overex-
pressed in DH, DCIS, and ductal carcinoma, but we
believe that this interpretation should be made with caution
because rare cycling healthy breast cells also express
HPC–HPH/PRC1 complex genes. Future molecular stud-
ies should determine whether frequent detection of BMI-1
and its binding partners in breast carcinoma is reflective of
actual overexpression of these genes.
In contrast to HPC–HPH/PRC1 complex proteins, the
expression profile of the EED–EZH/PRC2 complex gene
EZH2 was clearly related to loss of differentiation and
development of breast carcinoma. Similar to healthy breast
gland cells, EZH2 was infrequently detected in DH, low-
grade DCIS, and well-differentiated invasive carcinoma.
However, EZH2+ cells were abundant in DCIS and invasive
carcinomas of high grade, as confirmed using a tissue
array of a separate group of 172 breast carcinomas.
Interestingly, increased expression of EZH2 in breast car-
cinomas is in line with the recent observation that Myc-
derived experimental breast tumors in mice overexpress
the EZH2 homologue Enx1 [53]. In the current study, we
show that increased expression of EZH2 in poorly differ-
entiated DCIS results in coexpression of EZH2 with BMI-1
and other PcG proteins of the HPC–HPH complex. A
minority of these BMI-1/EZH2 double-positive cells
expressed MIB-1/Ki-67, suggesting that only a fraction of
them was cycling. The high frequency of EZH2 expression
in high-grade invasive carcinomas also resulted in frequent
BMI-1/EZH2 coexpression, but in this case, virtually all
BMI-1/EZH2 double-positives were MIB-1/Ki-67+ and divid-
ing. This pattern suggests an increased rate of cell division
within this population as opposed to BMI-1+/EZH2+ cells in
high-grade DCIS. We were unable to determine whether
increased EZH2 expression in BMI-1+ cells contributed to
enhanced cell division or malignant transformation because
our study is cross-sectional. The limited expression of
MIB-1 in BMI-1+/EZH2+ neoplastic cells of poorly differen-
tiated DCIS, in addition to the fact that cycling neoplastic
cells of low-grade invasive carcinomas rarely express
EZH2, indicates that EZH2 expression in breast carcinoma
is not necessarily related to proliferation. However, trans-
fection experiments of EZH2 to the Ramos cell line recent-
ly demonstrated that increased expression of EZH2 results
in increased proliferation [49], whereas treatment of EZH2+
prostate cancer cells with small interfering RNA targeted
against EZH2 produced inhibition of cell proliferation [39].
These experimental data suggest that a contribution of
EZH2 to altered proliferative behavior of high-grade breast
cancer cells is at least theoretically possible. Increasing
data suggest that low-grade and high-grade breast cancers
evolve through quite different genetic pathways [54].
Therefore, some of the differences in PcG expression level
may reflect these different backgrounds, rather than being
causal events. This will be the subject of further inves-
tigations. To which extent the described changes in ex-
pression of PcG proteins relate to the putative cell of origin
within the glandular/myoepithelial cell concept of breast
carcinogenesis [55] is difficult to say. It is possible that
EZH2 is expressed in cells with a more stem cell pheno-
type, especially when they are dividing. To investigate this,
further double stainings for EZH2 and cytokeratins are
necessary.
An estimated one-third to half of DCIS are predicted to
progress to invasive carcinoma if left untreated. We pro-
pose that enhanced expression of EZH2 in BMI-1+ cells of
DCIS contributes to loss of cell identity in high-grade
breast carcinomas, and that increased EZH2 expression
precedes high proliferation. The recent observation that
progression of prostate cancer to an invasive phenotype is
also associated with enhanced expression of EZH2 [39,56]
strongly suggests that altered expression of PcG genes is
an important contributing factor in the development of
neoplasms in humans.
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